In a 59-year-old female with hypertension treated with telmisartan, amlodipine, and bisoprolol who presented with abdominal distension, bilateral leg edema, and shortness of breath, was started on rabeprazole and oral furosemide, and now is hemodynamically stable but has persistent abdominal heaviness and occasional exertional dyspnea, should she be admitted to the hospital or referred for outpatient cardiology evaluation?

This patient should be referred for urgent outpatient cardiology evaluation with echocardiogram and BNP/NT-proBNP within 1-2 days, rather than immediate hospitalization, given her hemodynamic stability and clinical improvement on diuretics.

Clinical Assessment

This 59-year-old woman presents with a constellation of findings highly suggestive of new-onset heart failure: bilateral leg edema, abdominal distension with dyspnea, exertional shortness of breath, and partial response to diuretics. Her current BP of 150/90 mmHg, while elevated, does not meet criteria for hypertensive emergency (no acute end-organ damage) 1. The slightly elevated hemoglobin (154 g/L) may reflect hemoconcentration from diuresis rather than polycythemia.

Key clinical indicators favoring outpatient management:

• Hemodynamically stable (BP 150/90, improved from 184/106)
• Clinical improvement on oral furosemide
• No chest pain or acute coronary syndrome features
• Able to tolerate oral medications
• Home BP readings normal at 130/80

Red flags that would mandate hospitalization (currently absent):

• Acute cardiogenic pulmonary edema 1
• Severe hypertension with acute end-organ damage
• Resting hypoperfusion (cool extremities, narrow pulse pressure)
• Inability to achieve decongestion with oral diuretics 2, 3
• Acute coronary syndrome 4

Immediate Management Plan

Continue Current Therapy

Her existing antihypertensive regimen (telmisartan, amlodipine, bisoprolol) should be continued 5, 4, 3. In patients with suspected heart failure, guideline-directed medical therapy (GDMT) should be maintained during evaluation unless contraindicated 6, 3. The 2022 AHA/ACC/HFSA guidelines explicitly state that "preexisting GDMT should be continued and optimized" during heart failure evaluation 3.

Optimize Diuresis

• Increase furosemide to 40 mg PO daily (from the initial 20 mg dose) to achieve complete decongestion 2, 6
• Target: resolution of leg edema, abdominal distension, and dyspnea
• Monitor daily weights, with goal of 0.5-1 kg loss per day until euvolemic 2

Blood Pressure Management

Her current BP of 150/90 mmHg is suboptimal but does not require emergency intervention. Target BP should be <130/80 mmHg in the context of suspected heart failure 4. The combination of ARB (telmisartan), beta-blocker (bisoprolol), and calcium channel blocker (amlodipine) is appropriate per ESC guidelines 5.

Important caveat: While her triple therapy is guideline-concordant, patients with substantially elevated BP lacking acute end-organ damage can be treated with oral therapy adjustments rather than hospitalization 1.

Urgent Outpatient Workup (Within 1-2 Days)

Essential Diagnostic Tests

1. Transthoracic echocardiogram - to assess:

   • Left ventricular ejection fraction (distinguish HFrEF vs HFpEF)
   • Valvular function
   • Right ventricular function and filling pressures
   • Diastolic dysfunction 2, 3

2. BNP or NT-proBNP - elevated levels support heart failure diagnosis and guide therapy 2, 3. A reduction of ≥30% from baseline correlates with better outcomes 2.

3. Complete metabolic panel - assess:

   • Renal function (creatinine, BUN) - modest increases during diuresis are acceptable if transient and accompanied by successful decongestion 2, 6, 3
   • Electrolytes (particularly potassium) - critical given triple therapy with ARB, beta-blocker, and potential for increased diuretics 6, 7

4. Electrocardiogram - evaluate for ischemia, arrhythmias, or conduction abnormalities 1, 3

5. Chest X-ray (if not already done) - assess for pulmonary congestion, cardiomegaly 1

Monitoring Parameters

• Daily weights at same time each day
• Fluid intake/output monitoring
• Symptom diary (dyspnea, orthopnea, edema)
• Home BP monitoring twice daily 6, 3

Medication Safety Considerations

Current Regimen Assessment

Her triple therapy (telmisartan + amlodipine + bisoprolol) is evidence-based for hypertension and heart failure 5, 4, 5. However:

Bisoprolol: One of three beta-blockers (with carvedilol and metoprolol succinate) proven to improve outcomes in heart failure 4. Should be continued unless signs of decompensation worsen 6, 3.

Telmisartan: ARBs are equivalent to ACE inhibitors for heart failure with reduced ejection fraction 4. Continue current dose 8.

Amlodipine: Safe in heart failure (PRAISE trial) and appropriate for additional BP control 5, 4, 5. While rare case reports describe non-cardiogenic pulmonary edema with amlodipine 9, this patient's presentation is more consistent with cardiogenic causes given bilateral leg edema and response to diuretics.

Furosemide: Monitor for electrolyte abnormalities, particularly hypokalemia and hyponatremia 7. Serum electrolytes should be checked within 3-5 days of dose increase.

Potential Medication Adjustments

If echocardiogram confirms HFrEF (LVEF <40%), consider adding:

• Mineralocorticoid receptor antagonist (MRA) such as spironolactone - Class I recommendation for NYHA class II-IV heart failure 5, 4, 5
• Monitor potassium closely given concurrent ARB use 5, 6

Clinical Pitfalls to Avoid

1. Do not discontinue GDMT prematurely: Modest increases in creatinine (up to 0.5 mg/dL) during diuresis are acceptable and not associated with worse outcomes if decongestion is achieved 2, 6, 3.

2. Do not over-diurese: Target is clinical euvolemia (no edema, no dyspnea), not arbitrary weight loss 2.

3. Avoid excessive BP lowering: While target is <130/80 mmHg, avoid diastolic BP <60 mmHg, especially in older patients, as this may worsen myocardial ischemia 4.

4. Monitor for worsening renal function: While transient creatinine elevation is acceptable, sustained or marked increases warrant reassessment 6, 8.

Follow-up Timeline

• Cardiology appointment: Within 1-2 days with echocardiogram
• Lab recheck: 3-5 days (electrolytes, renal function)
• Primary care follow-up: 1 week to review results and adjust therapy
• Return precautions: Worsening dyspnea at rest, chest pain, inability to lie flat, weight gain >2 kg in 2 days, or inability to tolerate oral medications → go to emergency department immediately

This outpatient approach is appropriate because the patient is hemodynamically stable, improving on oral therapy, and lacks features of acute decompensated heart failure requiring intravenous therapy 2, 6, 3. The 2019 ACC Expert Consensus and 2022 AHA/ACC/HFSA guidelines support continuing oral diuretics and GDMT in stable patients while completing diagnostic evaluation 2, 3.